Pre-Submission Review for Proteomics Papers

Proteomics reviewers often ask:

• are sample collection, lysis, digestion, enrichment, fractionation, and cleanup described enough?
• are biological and technical replicates separated correctly?
• are acquisition settings, instrument type, search parameters, and databases clear?
• is false discovery rate controlled at the right level?
• are protein groups, peptides, isoforms, PTMs, and quantification handled carefully?
• are missing values, batch effects, normalization, and multiple testing addressed?
• are claims validated by targeted assays, orthogonal methods, or biological perturbation when needed?
• are raw and processed data deposited in PRIDE, ProteomeXchange, or another appropriate repository?
• does the paper fit Molecular & Cellular Proteomics, Proteomics, Journal of Proteome Research, a biology venue, or a clinical journal?

The manuscript has to make the protein evidence traceable.

In our pre-submission review work, proteomics papers most often fail when the biological story is stronger than the protein evidence trail.

Sample-prep opacity: tissue handling, depletion, enrichment, digestion, cleanup, or storage conditions are underreported.

Replication blur: technical runs are described as if they were independent biological evidence.

FDR mismatch: the paper reports discovery findings without making clear how identification confidence was controlled.

Pathway overreach: pathway enrichment is used as mechanism when the actual protein changes are exploratory.

Repository risk: raw files, search outputs, metadata, and processed matrices are not ready for PRIDE or ProteomeXchange review.

A useful review should identify the first proteomics-specific objection a reviewer would raise.

PRIDE and ProteomeXchange exist because proteomics reviewers need access to raw and processed mass-spec evidence, not only summarized tables. HUPO Proteomics Standards Initiative work has pushed the field toward richer reporting of proteomics experiments, including standards for experimental metadata and proteoform or peptidoform representation.

Molecular & Cellular Proteomics and other proteomics venues expect enough methodological detail for reviewers to assess identification, quantification, and interpretation. Biomedical journals such as JCI also list proteomics among data types that should be deposited in appropriate repositories when they support the manuscript.

These expectations mean the deposition plan is not an administrative afterthought. It is part of scientific readiness.

Send the manuscript, target journal, sample table, cohort or biological-material description, sample-preparation protocol, instrument method, search settings, database version, FDR approach, quantification workflow, normalization and missing-data plan, statistics code if available, validation plan, PRIDE or ProteomeXchange accession plan, figures, supplement, and prior reviewer comments.

For PTM papers, include enrichment details, localization probability, site assignment logic, and whether site-level claims are supported. For clinical proteomics, include cohort design, sample handling, batch structure, and confounder plan.

A useful proteomics pre-submission review should include:

• protein-evidence claim verdict
• sample-preparation and replication critique
• acquisition and search-parameter review
• identification, FDR, and quantification check
• validation and pathway-interpretation review
• repository and metadata readiness note
• journal-lane recommendation
• submit, revise, retarget, or diagnose deeper call

The review should not only say "deposit data." It should identify whether the current data package lets reviewers audit the claim.

Before submission, authors often need to:

• separate biological and technical replication clearly
• add sample handling and preprocessing detail
• clarify search database, FDR, and protein grouping
• add missing-value, normalization, and batch analysis
• limit pathway claims to what protein evidence supports
• add targeted or orthogonal validation
• prepare raw files, processed matrices, metadata, and repository accessions
• retarget from a broad biology journal to a proteomics, methods, or clinical venue when the contribution is narrower

These fixes make the protein-level claim easier to trust.

A discovery proteomics paper needs transparent sample prep, FDR discipline, and restrained pathway interpretation. A targeted proteomics paper needs assay specificity, calibration, limit of detection, and quantification logic. A phosphoproteomics paper needs site localization and enrichment detail. An interactomics paper needs controls and nonspecific-binding safeguards. A clinical proteomics paper needs cohort design, pre-analytical variation, batch correction, and validation. A multi-omics paper needs to show how protein evidence changes the biological inference rather than merely decorating RNA results.

The AI manuscript review can flag whether the blocking risk is sample prep, FDR, validation, data deposition, or journal fit.

Use this page when the manuscript's submission risk depends on protein measurement, mass spectrometry, peptide evidence, protein groups, PTMs, protein quantification, targeted proteomics, or proteomics data deposition. Use genomics or transcriptomics review when the main evidence is DNA or RNA. Use molecular biology review when the manuscript is a broader mechanistic story and proteomics is only one supporting assay.

That distinction keeps the page focused on the proteomics buyer's actual problem.

Do not submit a proteomics paper if the protein evidence cannot be traced from raw data to figure claim. Reviewers should be able to understand how spectra, peptides, protein groups, normalization, and statistics support the result.

Also pause if the repository package is not ready. A vague promise to upload later can create friction because reviewers may need raw files, processed outputs, and metadata to judge the analysis.

For PTM papers, pause if site localization is weak. A biological claim about a modified residue needs evidence at the site level, not only a pathway-level story.

For clinical proteomics, pause if sample handling and batch structure are underreported. Differences in collection, storage, processing date, depletion, or instrument run can explain a biomarker signal.